Business Context and Reporting Period
This Form 8-K is a current report filed by ReWalk Robotics Ltd. (noting a discrepancy in the request metadata which listed "Lifeward Ltd.") on December 14, 2016. The filing addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific financial statements, revenue figures, profit margins, cash flow data, or debt levels. The only quantitative financial metric disclosed is the regulatory threshold for the Market Value of Listed Securities (MVLS), which is set at $50,000,000. The filing notes that the company failed to meet this MVLS requirement as well as alternative standards for total assets and total revenue.
Material Changes
The primary material event is the receipt of a deficiency notice from Nasdaq on December 14, 2016. The company failed to satisfy the minimum $50,000,000 MVLS requirement under Nasdaq Listing Rule 5450(b)(2)(A) and did not meet the alternative total assets and total revenue standards under Rule 5450(b)(3)(A). This notice does not constitute an immediate delisting; trading of ordinary shares under the symbol "RWLK" continues on The Nasdaq Global Market.
Outlook, Risks, and Management Commentary
- Compliance Period: Nasdaq has granted the company a 180-day compliance period, ending June 12, 2017, to regain compliance.
- Path to Compliance: The company can regain compliance if the MVLS closes at $50,000,000 or more for 10 consecutive business days, or by reporting stockholders' equity of $10 million or more.
- Delisting Risk: If compliance is not achieved by June 12, 2017, the company faces potential delisting. In such an event, the company may appeal to a Nasdaq Hearings Panel or apply to transfer listing to The Nasdaq Capital Market.
- Forward-Looking Risks: The filing lists significant risks including the ability to increase sales, achieve market acceptance, secure third-party reimbursement, complete clinical research, manage FDA surveillance studies, resolve shareholder class action litigation, repay secured indebtedness, and secure capital through equity distribution programs.
Investor Verification Checklist
- Verify the current Market Value of Listed Securities (MVLS) to assess proximity to the $50,000,000 threshold.
- Review the most recent Form 10-K or 10-Q to confirm stockholders' equity levels relative to the $10 million alternative compliance standard.
- Monitor the company's progress on the mandatory post-market 522 surveillance study and FDA regulatory actions.
- Check for updates regarding the ongoing shareholder class action litigation related to the initial public offering.
- Assess the company's ability to repay secured indebtedness and secure additional capital given the listing deficiency.